A Maryland-based life sciences company has reported positive results in the most recent phase of testing of its new mesothelioma medication, and will be moving forward with the next phase with high hopes. In conducting its Phase I clinical trial, MaxCyte is testing a higher dose of its proprietary mesothelin-targeting chimeric antigen receptor (CAR) therapy on a third cohort of patients diagnosed with peritoneal mesothelioma as well as with ovarian cancer.
The patients that the company’s treatment protocol targets are those who have ovarian cancer or peritoneal mesothelioma that is either relapsed or refractory, meaning that it is not responding to treatment. The second cohort, which was just completed, revealed that infusions of MCY-M11, administered intraperitoneally, were well tolerated in the patients on whom it was administered, with no infusion-related adverse events, toxicities or other unwanted impacts seen. The Phase I clinical trial is looking for the appropriate levels of effectiveness that will still be safe and tolerable.
Speaking of the success that they have seen thus far in mesothelioma patients, the company’s Chief Medical Officer Claudio Dansky Ullmann, MD said, “We are making significant progress with our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform. Furthermore, the on-going trial continues to demonstrate the feasibility of our one-day cell therapy manufacturing process. We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumors where the majority of patients still have very limited treatment options.” If it continues to be tested successfully, MCY-M11 will be used to treat platinum-resistant cancers of the ovaries, primary peritoneum and fallopian tube, as well as those diagnosed with advanced peritoneal mesothelioma that returns after chemotherapy. The tests are being conducted at the National Cancer Institute at the National Institutes of Health and at Washington University at St. Louis.
Mesothelioma victims look to researchers for aggressive treatment options and to the legal system for justice. If you have been diagnosed with malignant mesothelioma and you need information, contact us today at 1-800-966-2244.